Company Overview and News

 
Oligarch Chat: Sumal wants to avoid tax, Harry wants Rs25bn, and Pathirage wants a dictator

2018-09-02 lankabusinessonline
September 2, 2018 (LBO) – As video clips move through traditional and social media, the public is abuzz about the comments made by some of Sri Lanka’s most powerful businessmen at the ‘Fireside Chat’ event last week at the Colombo Hilton.
AEL

 
Dhammika strikes patriotic note among Sri Lanka’s oligarchs

2018-08-31 lankabusinessonline
August 31, 2018 (LBO) – Arguably Sri Lanka’s richest man, Dhammika Perera struck a patriotic tone at the recent “fireside chat” event at the Colombo Hilton.
AEL

 
Foreign Investors stumble with investment in shares of Sri Lanka’s Access Engineering (AEL)

2018-06-13 lankabusinessonline
June 13, 2018 (LBO) – Due to the lacklustre performance of the Colombo Stock Exchange, foreign investors likely have made significant losses investing in Sri Lankan stocks over the past few years. Some of the largest losses in percentage terms are likely to be investments made in shares of Sri Lankan listed Access Engineering (AEL).
AEL

 
Norges Bank stumbles with its investment in shares of Sri Lanka’s Access Engineering (AEL)

2018-06-13 lankabusinessonline
June 13, 2018 (LBO) – Norges Bank, an investment arm of the Norwegian Sovereign Wealth Fund, appears to have made significant losses investing in Sri Lankan stocks over the past 3 years. One of the largest losses in percentage terms is likely to be its investment in Sri Lankan listed Access Engineering (AEL).
AEL

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

18h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

18h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

20h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to CSE:AEL / ACCESS ENGINEERING PLC on message board site Silicon Investor.

Michael Slager, whatu0027s the truth? Michael Slager, whatu0027s the truth? Michael Slager, whatu0027s the truth? Michael Moore Is a Big Fat Idiot Michael Moore Is a Big Fat Idiot Michael Moore Is a Big Fat Idiot
Ask Michael Burke Ask Michael Burke Ask Michael Burke Israel to U.S. : Now Deal with Syria and Iran Israel to U.S. : Now Deal with Syria and Iran Israel to U.S. : Now Deal with Syria and Iran
Michael Lauer/Lancer Funds Michael Lauer/Lancer Funds Michael Lauer/Lancer Funds Israeli stocks Israeli stocks Israeli stocks
The Arab-Israeli Solution The Arab-Israeli Solution The Arab-Israeli Solution ESLTF (Elbit Systems Ltd) an Israelian arms manufacturer ESLTF (Elbit Systems Ltd) an Israelian arms manufacturer ESLTF (Elbit Systems Ltd) an Israelian arms manufacturer
Fahrenheit 9/11: Michael Mooreu0027s Masterpiece Fahrenheit 9/11: Michael Mooreu0027s Masterpiece Fahrenheit 9/11: Michael Mooreu0027s Masterpiece The Peter and Michael, loving Margolies thread The Peter and Michael, loving Margolies thread The Peter and Michael, loving Margolies thread